Water and Sodium Balance

Radioactive sodium iodine 131I radioiodine

Statins (HMG-CoA reductase inhibitors) - a class of drug used to lower cholesterol levels

Statins (or HMG-CoA reductase inhibitors) are a class of drug used to lower cholesterol levels by inhibiting the enzyme HMG-CoA reductase, which plays a central role in the production of cholesterol...

Types of laxatives

Laxatives are medicines that relieve constipation (difficulty with bowel movements). They are a popular type of over-the-counter remedy. They can also be prescribed for conditions that could get wor...

KYNAMRO

KYNAMRO (mipomersen sodium) injection is an oligonucleotide inhibitor of apolipoprotein B-100 synthesis indicated as an adjunct to lipid-lowering medications and diet to reduce low density lipoprote...

Kowa/Lilly's statin Livalo beats pravastatin in LDL-C lowering in Phase IV study

Kowa Pharmaceuticals America's and Eli Lilly's Livalo (pitavastatin) met its primary endpoint in the Phase IV PREVAIL clinical trial when it proved superior to pravastatin (Bristol-Myers Squibb's Pr...

Pharmaceutical Research: Physiologically Based Modeling of Pravastatin Transporter-Mediated Hepatobiliary Disposition and Drug-Drug Interactions

Type: Original PaperPurposeTo develop physiologically based pharmacokinetic (PBPK) model to predict the pharmacokinetics and drug-drug interactions (DDI) of pravastatin, using the in vitro transport p...

Lilly, Kowa announce results from PREVAIL U.S. study

Kowa Pharmaceuticals America, Inc. and Eli Lilly and Company today announced results of the PREVAIL U.S. study (Pitavastatin compaREd with praVAstatin In Lowering LDL-C in the U.S.) which evaluated th...

Lilly and Kowa's Livalo meets primary endpoint of LDL-C reduction

Presenting at the National Lipid Association's (NLA) Scientific Sessions in Scottsdale, Arizona, USA, Kowa Pharmaceuticals America, a subsidiary of privately owned Japanese firm Kowa, and US drug majo...

Some higher-potency statins linked with diabetes

Taking certain higher-potency statins could put patients at a higher risk of developing diabetes than taking lower-potency statins, a BMJ study indicates (online, 23 May 2013). Over a 14-year stu...

New Data Showed LIVALO® (pitavastatin) Met…

New Data Showed LIVALO® (pitavastatin) Met Primary Endpoint of LDL-C Reduction When Compared with Pravastatin

Eli Lilly's Livalo: A Big Win For Patients And Investors

ByStock Maelstrom:Eli Lilly (LLY) and Kowa Pharmaceuticals (KPA) together announced that Livalo, a cholesterol reducing drug has better effects than the alternative treatment, pravastatin in HIV-infec...

Pharmaceutical Research: Comment on the Article “Physiologically Based Modeling of Pravastatin Transporter-Mediated Hepatobiliary Disposition and Drug-Drug Interactions”

Type: LetterNo abstract available.

Efficacy and safety of adding fenofibrate 160 mg in high-risk patients with mixed hyperlipidemia not controlled by pravastatin 40 mg monotherapy.

Patients with mixed hyperlipidemia and at high risk of coronary heart disease may not achieve recommended low-density lipoprotein (LDL) and non-high-density lipoprotein (non-HDL) cholesterol goals on...

The effects of a SNP in SLCO1B1 on the pharmacodynamics of pravastatin.

What is already known about this subject The SNP rs4149056 is associated with altered statin pharmacokinetics and increased risk of statin intolerance. LDL-cholesterol lowering by simvastatin is also...

Effects of 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitor pravastatin on membrane lipids and membrane associated functions of Methanothermobacter thermautotrophicus.

The role of archaeal membrane and its lipid constituents was investigated in bioenergetic functions of Methanothermobacter thermautotrophicus. The effects were determined of the 3-hydroxy-3-methylglut...

Effect of Pravastatin on Bleomycin-induced Acute Lung Injury and Pulmonary Fibrosis.

SUMMARY 1. Pravastatin is best known for its antilipidemic action. Recent studies have demonstrated that statins have immunomodulatory and anti-inflammatory effects. The present study aimed to determi...

Intestinal Absorption of HMG-CoA Reductase Inhibitor Pravastatin Mediated by Organic Anion Transporting Polypeptide.

PURPOSE: The purpose of this study is to clarify the impact of organic anion transporting polypeptide (Oatp) on intestinal absorption of the HMG-CoA reductase inhibitor, pravastatin. METHODS: OATP/Oat...